Blueprint Medicines Corp

NASDAQ:BPMC   12:49:42 PM EDT
91.93
+0.98 (+1.08%)
Products, Regulatory

Blueprint Medicines Announces Positive Top-Line Results From Explorer And Pathfinder Trials Of Ayvakit

Published: 09/22/2020 11:20 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Announces Positive Top-line Results From Explorer and Pathfinder Trials of Ayvakit™ (avapritinib) in Patients With Advanced Systemic Mastocytosis.
Blueprint Medicines Corp - 76% Confirmed Orr in Explorer, With a Median Duration of Response of 38.3 Months.
Blueprint Medicines Corp - 75% Confirmed Orr in Pathfinder, With a Median Duration of Response Not Reached.
Blueprint Medicines Corp - Ayvakit Safety Profile Reinforced at 200 Mg Qd Dose in Advanced Sm.
Blueprint Medicines Corp - Plan to Submit Supplemental New Drug Application to FDA for Advanced Sm in Q4.